Does it matter whether or not a lipid-lowering agent inhibits rho kinase?

Current Atherosclerosis Reports

Volumn 9, Issue 5, 2007, Pages 384-388

  Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANTILIPEMIC AGENT; FASUDIL; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; RHO KINASE; RHO KINASE INHIBITOR; ROSUVASTATIN; UNCLASSIFIED DRUG;

BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS; RHO-ASSOCIATED KINASES;

EID: 36148972466     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-007-0049-9     Document Type: Review

References (50)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
2. Buchwald H, Varco RL, Matts JP, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946-955.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
4. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
5. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
6. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
7. Pekkanen J, Linn S, Heiss G, et al.: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990, 322:1700-1707.
8. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440-1445.
9. Corsini A, Bellosta S, Baetta R, et al.: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84:413-428.
10. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
11. Van Aelst L, D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev 1997, 11:2295-2322.
12. Hall A: Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
13. Takemoto M, Sun J, Hiroki J, et al.: Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002, 106:57-62.
14. Laufs U, Endres M, Stagliano N, et al.: Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 2000, 106:15-24.
15. Hall A: Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol 1994, 10:31-54.
16. Uehata M, Ishizaki T, Satoh H, et al.: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389:990-994.
17. Katsumata N, Shimokawa H, Seto M, et al.: Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. Circulation 1997, 96:4357-4363.
18. Shimokawa H: Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002, 39:319-327.
19. Fukata Y, Amano M, Kaibuchi K: Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001, 22:32-39.
20. Sato M, Tani E, Fujikawa H, Kaibuchi K: Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000, 87:195-200.
21. Masumoto A, Mohri M, Shimokawa H, et al.: Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002, 105:1545-1547.
22. Masumoto A, Hirooka Y, Shimokawa H, et al.: Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001, 38:1307-1310.
23. Abe K, Shimokawa H, Morikawa K, et al.: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004, 94:385-393.
24. Wolfrum S, Dendorfer A, Rikitake Y, et al.: Inhibition of rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004, 24:1842-1847.
25. Ito K, Hirooka Y, Kishi T, et al.: Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 2004, 43:156-162.
26. Ito K, Hirooka Y, Sakai K, et al.: Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res 2003, 92:1337-1343.
27. Rikitake Y, Kim HH, Huang Z, et al.: Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005, 36:2251-2257.
28. Kataoka C, Egashira K, Inoue S, et al.: Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002, 39:245-250.
29. Sawada N, Itoh H, Ueyama K, et al.: Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000, 101:2030-2033.
30. Shibata R, Kai H, Seki Y, et al.: Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing Bax expression and apoptosis. J Cardiovasc Pharmacol 2003, 42(Suppl 1):S43-47.
31. Eto Y, Shimokawa H, Hiroki J, et al.: Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol 2000, 278:H1744-1750.
32. Ikeda F, Terajima H, Shimahara Y, et al.: Reduction of hepatic ischemia/reperfusion-induced injury by a specific ROCK/Rho kinase inhibitor Y-27632. J Surg Res 2003, 109:155-160.
33. Bao W, Hu E, Tao L, et al.: Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 2004, 61:548-558.
34. Mallat Z, Gojova A, Sauzeau V, et al.: Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 2003, 93:884-888.
35. Miyata K, Shimokawa H, Kandabashi T, et al.: Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 2000, 20:2351-2358.
36. Hattori T, Shimokawa H, Higashi M, et al.: Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004, 109:2234-2239.
37. Funakoshi Y, Ichiki T, Shimokawa H, et al.: Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001, 38:100-104.
38. Takeda K, Ichiki T, Tokunou T, et al.: Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001, 21:868-873.
39. Kawamura H, Yokote K, Asaumi S, et al.: High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2004, 24:276-281.
40. Hiroki J, Shimokawa H, Higashi M, et al.: Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004, 37:537-546.
41. Buyukafsar K, Arikan O, Ark M, et al.: Upregulation of Rho-kinase (ROCK-2) expression and enhanced contraction to endothelin-1 in the mesenteric artery from lipopolysaccharide-treated rats. Eur J Pharmacol 2004, 498:211-217.
42. Liu PY, Chen JH, Lin LJ, Liao JK: Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 2007, 49:1619-1624.
43. Rikitake Y, Liao JK: Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-I expression in vascular endothelial cells. Circulation 2005, 111:3261-3268.
44. Toshima Y, Satoh S, Ikegaki I, Asano T: A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000, 31:2245-2250.
45. Bivalacqua TJ, Champion HC, Usta MF, et al.: RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 2004, 101:9121-9126.
46. Nishikimi T, Akimoto K, Wang X, et al.: Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004, 22:1787-1796.
47. Higashi M, Shimokawa H, Hattori T, et al.: Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003, 93:767-775.
48. Matsumoto Y, Uwatoku T, Oi K, et al.: Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004, 24:181-186.
49. Noma K, Goto C, Nishioka K, et al.: Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol 2007, 49:698-705.
50. Nohria A, Grunert ME, Rikitake Y, et al.: Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006, 99:1426-1432.